Ultra Market Research | Global EGFR and HER2 Targeted Non Small Cell Lung Cancer (NSCLC)Market
Global EGFR and HER2 Targeted Non Small Cell Lung Cancer (NSCLC)Market
Report ID : 851
Category : Pharmaceuticals,Global
No Of Pages : 123
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
The Global EGFR & HER2 Targeted NSCLC (Non-Small Cell Lung Cancer) Market has emerged as a crucial segment of oncology therapeutics. EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal Growth Factor Receptor 2) targeted therapies address specific mutations responsible for aggressive cancer progression, offering a tailored approach to treatment. These therapies are widely used in managing advanced and metastatic NSCLC cases, where traditional options fail to yield effective outcomes. Recent advancements in precision medicine, including next-generation sequencing and companion diagnostics, have further propelled the adoption of EGFR & HER2 inhibitors. Moreover, a surge in global clinical trials and FDA approvals highlights the potential for substantial growth in this market.
Market Segmentation
EGFR Targeted Therapies Targeted Inhibitors
First-Generation Inhibitors
Second-Generation Inhibitors
Third-Generation Inhibitors
Others
Monoclonal Antibodies
Anti-EGFR Monoclonal Antibodies
Dual Targeted Antibodies
Bispecific Antibodies
Others
Combination Therapies
EGFR + HER2 Inhibitors
EGFR + Chemotherapy Combinations
Others
HER2 Targeted Therapies HER2 Inhibitors
Small Molecule Inhibitors
Monoclonal Antibodies
Others
HER2-Targeting ADCs (Antibody-Drug Conjugates)
First-Generation ADCs
Second-Generation ADCs
Others
Combination Therapies
HER2 + EGFR Therapies
HER2 + Immunotherapies
Others
Market Players
AstraZeneca (United Kingdom)
Roche Holding AG (Switzerland)
Eli Lilly and Company (United States)
Novartis AG (Switzerland)
Pfizer Inc. (United States)
Amgen Inc. (United States)
Boehringer Ingelheim (Germany)
Takeda Pharmaceutical Company (Japan)
Johnson & Johnson (United States)
Bristol Myers Squibb (United States)
Sanofi (France)
Merck & Co., Inc. (United States)
AbbVie Inc. (United States)
Bayer AG (Germany)
Genentech, Inc. (United States)
Drivers
The market's growth is driven by an increasing prevalence of NSCLC worldwide, with EGFR and HER2 mutations becoming more identifiable due to advancements in diagnostic technologies. Targeted therapies provide personalized treatment options with higher efficacy and fewer side effects, significantly enhancing patient outcomes. Supportive regulatory frameworks and accelerated FDA approvals for EGFR and HER2 inhibitors, such as osimertinib and trastuzumab deruxtecan, further bolster market expansion. Rising healthcare investments and growing awareness of precision medicine also contribute to increased adoption of targeted therapies in oncology.
Restraints
Challenges include the high cost of EGFR & HER2 targeted therapies, which limits accessibility for patients in low-income regions. Additionally, resistance mechanisms to targeted therapies, such as T790M mutations or HER3 pathway activation, reduce long-term efficacy. Regulatory complexities and stringent approval processes can also hinder the entry of novel therapies into the market. Moreover, the need for robust infrastructure for companion diagnostics adds financial and operational burdens, especially in developing economies.
Opportunities
Emerging markets present significant opportunities for expanding the reach of EGFR & HER2 targeted therapies. Investments in companion diagnostics and next-generation sequencing are enabling more precise mutation identification, facilitating early intervention. The development of combination therapies addressing resistance mechanisms offers promising avenues for enhancing treatment outcomes. Collaborations between pharmaceutical companies and research institutions to develop innovative drugs and expand indications for existing therapies could also unlock new revenue streams.
Trends
Key trends include the integration of artificial intelligence and big data analytics in identifying actionable mutations and personalizing treatment regimens. Biosimilar development is gaining traction, offering cost-effective alternatives to branded EGFR & HER2 inhibitors. Furthermore, the rise of liquid biopsies for non-invasive diagnostics is revolutionizing mutation monitoring and resistance detection. The shift toward combination therapies, such as dual inhibition strategies, is redefining therapeutic approaches for advanced NSCLC.
Approved Products
Osimertinib (Tagrisso)
Gefitinib (Iressa)
Erlotinib (Tarceva)
Trastuzumab deruxtecan (Enhertu)
Afatinib (Gilotrif)
Pipeline/Registered/Pre-Registered Products
Lazertinib (Clinical Trials Phase III)
Poziotinib (Regulatory Review)
Amivantamab (Pre-Registered)
HER2 ADC ZW25 (Early-Stage Development)
Key Target Audience
Oncology Research Centers
Pharmaceutical and Biotechnology Companies
Healthcare Providers and Institutions
Diagnostic Laboratories
Regulatory Agencies
FAQs
EGFR and HER2 are proteins involved in cell signaling pathways that promote cancer growth. Targeted therapies against these proteins help manage NSCLC by inhibiting these pathways.
Increased prevalence of NSCLC, advancements in diagnostic technologies, and the efficacy of targeted therapies drive their adoption.
North America and Europe lead due to high healthcare investments and advanced diagnostic infrastructure.
High therapy costs, resistance mechanisms, and stringent regulatory requirements pose significant challenges.
Emerging markets and innovations in combination therapies are expected to drive robust growth.
Executive Summary
Key Highlights of the Global EGFR & HER2 Targeted NSCLC Market
Table 7: Opportunities in Emerging Markets and Technological Advancements
Table 8: Approved Products in the EGFR & HER2 Targeted NSCLC Market
Table 9: Pipeline, Registered, and Pre-Registered Products Overview
Table 10: Target Audience and Their Role in Market Growth
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Global EGFR & HER2 Targeted NSCLC (Non-Small Cell Lung Cancer) Marketand its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Global EGFR & HER2 Targeted NSCLC (Non-Small Cell Lung Cancer) Marketfor the past year and forecasts for the next six years. Global Lung Cancer Diagnostics Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Global EGFR & HER2 Targeted NSCLC (Non-Small Cell Lung Cancer) Marketcategories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Global EGFR & HER2 Targeted NSCLC (Non-Small Cell Lung Cancer) Marketfrom different application industries in different regions.
